Jessica Zhang

VP of Strategic Development at Huasai BioMed Inc . Lmt.

Presenter

Dr. Xinhua Zhang is a distinguished leader in Cell and Gene Therapy (CGT) with over 20 years of experience in the United States. Holding a PhD in CGT from Fudan University and a postdoctoral fellowship at the University of Pennsylvania, Dr. Zhang has made significant contributions to the field, playing a pivotal role in the process development, manufacturing, quality control, and registration of 8 out of 40 FDA-approved CGT drug products, including the first AAV, CAR-T, TIL, and MSC products. Her career includes leadership roles such as Principal Scientist, Director of Quality, Senior Director of CMC at prominent organizations like WuXi AppTec ATU, CAROT at the University of Pennsylvania, VintaBio Inc., and Frontage Laboratories. Dr. Zhang has been recognized for her scientific excellence, receiving funding from the Youth Foundation of the National Natural Science Foundation of China and the Postdoctoral Foundation of the American Heart Association. She have been certified by the Shanghai Committee of Science and Technology for advanced scientific achievements and honored as a Distinguished Academic by the American Heart Association. With over 40 peer-reviewed publications, Dr. Zhang is a respected reviewer for multiple academic journals and a frequent presenter at national and international conferences. Her expertise spans product research and development, process development, manufacturing, quality control, analytical development, quality assurance, quality system establishment, and drug registration, including NDA, IND, and BLA applications in both China and the USA. Dr. Zhang is currently the VP of Strategic Development, Huasai Biomed Inc.